Q-omics provides the consensus-scored ZNF70 profile across patient tissues and cancer cell-line models. ZNF70 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, ZNF70 is differentially expressed in 10, with the highest sampling consensus in KIRC. Additionally, ZNF70 RNA expression shows 21,045 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight ACC, and KIRC as cancer lineages where ZNF70 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ZNF70 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ZNF70 survival associations across molecular data types. ZNF70 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (4) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ZNF70 RNA expression–survival associations across cancer types. High ZNF70 expression shows unfavorable associations in ACC and LIHC, but favorable associations in UCS, THYM, HNSC and LUAD. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for ZNF70 RNA expression.
This table summarizes ZNF70 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10, while mass-spec protein shows differences in 3. The strongest signals are observed in KIRC for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for ZNF70. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ZNF70 shows lower tumor expression in THCA and higher tumor expression in KIRC, HNSC, LUSC, LUAD and LIHC. The KIRC box plot shows higher ZNF70 RNA expression in tumor versus normal tissue (log2 FC = +0.638, t-test p < 0.001).
This table shows molecular features associated with ZNF70 in patient tissues and cancer cell lines. In patient samples, ZNF70 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, ZNF70 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LIVER, while CRISPR and shRNA rows add functional-dependency signals in LARGE_INTESTINE and BLOOD_Lymphoma.
